Literature DB >> 28968188

The Opioid Epidemic: Crisis and Solutions.

Phil Skolnick1.   

Abstract

The widespread abuse of prescription opioids and a dramatic increase in the availability of illicit opioids have created what is commonly referred to as the opioid epidemic. The magnitude of this epidemic is startling: About 4% of the adult US population misuses prescription opioids, and in 2015, more than 33,000 deaths were attributable to overdose with licit and illicit opioids. Increasing the availability of medication-assisted treatments (such as buprenorphine and naltrexone), the use of abuse-deterrent formulations, and the adoption of US Centers for Disease Control and Prevention prescribing guidelines all constitute short-term approaches to quell this epidemic. However, with more than 125 million Americans suffering from either acute or chronic pain, the development of effective alternatives to opioids, enabled at least in part by a fuller understanding of the neurobiological bases of pain, offers the best long-term solution for controlling and ultimately eradicating this epidemic.

Entities:  

Keywords:  heroin; medication-assisted therapies; naloxone; overdose; pain; vaccines

Mesh:

Substances:

Year:  2017        PMID: 28968188     DOI: 10.1146/annurev-pharmtox-010617-052534

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  65 in total

1.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

2.  COVID-19 wash your hands but don't erase them from our profession - considerations on manual therapy past and present.

Authors:  Cameron W MacDonald; Peter G Osmotherly; Darren A Rivett
Journal:  J Man Manip Ther       Date:  2020-07

3.  COVID 19 and manual therapy: international lessons and perspectives on current and future clinical practice and education.

Authors:  C W MacDonald; E Lonnemann; S M Petersen; Darren A Rivett; P G Osmotherly; J M Brismée
Journal:  J Man Manip Ther       Date:  2020-07

4.  Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

Authors:  Daniel D Long; Scott R Armstrong; David T Beattie; Christina B Campbell; Timothy J Church; Pierre-Jean Colson; Sean M Dalziel; John R Jacobsen; Lan Jiang; Glenmar P Obedencio; Miroslav Rapta; Daisuke Saito; Ioanna Stergiades; Pamela R Tsuruda; Priscilla M Van Dyke; Ross G Vickery
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

5.  Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.

Authors:  Yun-Chi Chen; Chloe L Thio; Farin Kamangar; Andrea L Cox; Kjell J Wiberg
Journal:  J Viral Hepat       Date:  2020-08-02       Impact factor: 3.728

6.  Opioids in Adolescents' Homes: Prevalence, Caregiver Attitudes, and Risk Reduction Opportunities.

Authors:  Jane M Garbutt; Katharine Kulka; Sherry Dodd; Randall Sterkel; Kathryn Plax
Journal:  Acad Pediatr       Date:  2018-07-06       Impact factor: 3.107

Review 7.  Mechanisms of Immune Evasion and Bone Tissue Colonization That Make Staphylococcus aureus the Primary Pathogen in Osteomyelitis.

Authors:  Gowrishankar Muthukrishnan; Elysia A Masters; John L Daiss; Edward M Schwarz
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

8.  Trends in Abstinence and Retention Associated with a Medication-Assisted Treatment Program for People with Opioid Use Disorders.

Authors:  Kimberly D Brunisholz; Andrew J Knighton; Amulya Sharma; Lisa Nichols; Kristen Reisig; Jed Burton; Debbie Scovill; Carolyn Tometich; Mark Foote; Shelly Read; Scott Whittle
Journal:  Prog Community Health Partnersh       Date:  2020

9.  Development and validation of machine learning algorithms for postoperative opioid prescriptions after TKA.

Authors:  Akhil Katakam; Aditya V Karhade; Joseph H Schwab; Antonia F Chen; Hany S Bedair
Journal:  J Orthop       Date:  2020-03-28

10.  In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.

Authors:  Jennifer M Bossert; Eugene A Kiyatkin; Hannah Korah; Jennifer K Hoots; Anum Afzal; David Perekopskiy; Shruthi Thomas; Ida Fredriksson; Bruce E Blough; S Stevens Negus; David H Epstein; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2020-02-24       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.